Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2012 Aug 15;2012(8):CD007814.
doi: 10.1002/14651858.CD007814.pub2.

Histamine type 2 receptor antagonists as adjuvant treatment for resected colorectal cancer

Sanjeev Deva  1 , Michael Jameson
Affiliations
Meta-Analysis

Histamine type 2 receptor antagonists as adjuvant treatment for resected colorectal cancer

Sanjeev Deva et al. Cochrane Database Syst Rev. .

Abstract

Background: Anecdotal reports of tumour regression with histamine type 2 receptor antagonists (H(2)RAs) have lead to a series of trials with this class of drug as adjuvant therapy to try and improve outcomes in patients with resected colorectal cancers. There was a plausible scientific rationale suggesting merit in this strategy. This included improved immune surveillance (by way of increasing tumour infiltrating lymphocytes), inhibiting the direct proliferative effect of histamine as a growth factor for colorectal cancer and, in the case of cimetidine, inhibiting endothelial expression of E-selectin (a cell adhesion molecule thought to be critical for metastatic spread).

Objectives: To determine if H(2)RAs improve overall survival when used as pre- and/or postoperative therapy in colorectal cancer patients who have had surgical resection with curative intent. We also stratified the results to see if there was an improvement in overall survival in terms of the specific H(2)RA used.

Search methods: Randomised controlled trials were identified using a sensitive search strategy in the following databases: MEDLINE (1964 to present), the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library 2009), EMBASE (1980 to present) and Cancerlit (1983 to present).

Selection criteria: Criteria for study selection included: patients with colorectal cancer surgically resected with curative intent; H(2)RAs used i) at any dose, ii) for any length of time, iii) with any other treatment modality and iv) in the pre-, peri- or post-operative period. The results were stratified for the H(2)RA used.

Data collection and analysis: The literature search retrieved 142 articles. There were six studies included in the final analysis, published from 1995 to 2007, including a total of 1229 patients. All patients were analysed by intention to treat according to their initial allocation. Log hazard ratios and standard errors of treatment effects (on overall survival) were calculated using the Cochrane statistical package RevMan Version 5. Hazard ratios and standard errors were recorded from trial publications or, if not provided, were estimated from published actuarial survival curves using a spreadsheet designed for this purpose (http://www.biomedcentral.com/content/supplementary/1745-6215-8-16-S1.xls).

Main results: Of the six identified trials, five used cimetidine as the experimental H(2)RA, whereas one used ranitidine. There was a trend towards improved survival when H(2)RAs were utilised as adjuvant therapy in patients having curative-intent surgery for colorectal cancer (HR 0.70; 95% CI 0.48-1.03, P = 0.07). Analysis of the five cimetidine trials (n = 421) revealed a statistically significant improvement in overall survival (HR 0.53; 95% CI 0.32 to 0.87).

Authors' conclusions: Of the H(2)RAs evaluated cimetidine appears to confer a survival benefit when given as an adjunct to curative surgical resection of colorectal cancers. The trial designs were heterogeneous and adjuvant therapy has evolved since these trials were performed. Further prospective randomised studies are warranted.

PubMed Disclaimer

Conflict of interest statement

No declarations of interest.

Figures

1
1
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
2
2
Funnel plot of comparison: 1 Effect of H2RAs on survival in patients with colorectal cancer, outcome: 1.1 Overall Survival.
3
3
Forest plot of comparison: 1 Effect of H2RAs on survival in patients with early stage colorectal cancer, outcome: 1.1 Overall Survival.
4
4
Forest plot of comparison: 2 Overall Survival, outcome: 2.1 Cimetidine versus Ranitidine.
1.1
1.1. Analysis
Comparison 1 Effect of H2RAs on survival in patients with colorectal cancer, Outcome 1 Overall Survival.
2.1
2.1. Analysis
Comparison 2 Overall Survival, Outcome 1 Cimetidine versus Ranitidine.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD007814

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Adams 1994c {published data only}
    1. Adams WJ, Morris DL. Short‐course cimetidine and survival with colorectal cancer. Lancet 1994;344:1768. - PubMed
Finlay 1999 {published data only}
    1. Finlay IL, Dwerryhouse SJ, King J, King DW, Lubowski DZ, Morris DL. The effect of a short course of preoperative cimetidine in the grade of TIL in primary colorectal cancer ‐ a randomised controlled clinical trial.. GI cancer 1999;3(2):121‐7.
Huang 2007 {published data only}
    1. Huang WH, et al. Cimetidine as adjuvant treatment in rectal cancer. Chinese journal of cancer prevention and treatment 2007;14(8):623‐4.
Matsumoto 2002 {published data only}
    1. Matsumoto S, Imaeda Y, Umemoto S, Kobayashi K, Suzuki H, Okamoto T. Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis‐X and sialyl Lewis‐A epitope expression on tumour cells.. British Journal of Cancer 2002;86(2):161‐7. - PMC - PubMed
Nielsen 2002 {published data only}
    1. Nielsen HJ, Christensen IJ, Moesgaard F, Kehlet H. Ranitidine as adjuvant treatment in colorectal cancer. British Journal of Surgery 2002;89(11):1416‐22. - PubMed
Svendsen 1995 {published data only}
    1. Svendsen LB, Ross C, Knigge U, Frederiksen HJ, Graversen P, Kjaergård J, et al. Cimetidine as an Adjuvant Treatment in Colorectal Cancer. A double‐blind, randomized pilot study. Diseases of the colon and rectum 1995;38(5):514‐8. - PubMed

References to studies excluded from this review

Adams 1994a {published data only}
    1. Adams WJ, Morris DL, Ross WB, Lubowski DZ, King DW, Peters L. Cimetidine preserves non‐specific immune function after colonic resection for cancer. Aust NZ J Surg 1994;64(12):847‐52. - PubMed
Adams 1994b {published data only}
    1. Adams WJ, Lawson JA, Morris DL. Cimetidine inhibits in vivo growth of human colon cancer and reverses histamine stimulated in vitro and in vivo growth. Gut 1994;35(11):1632‐6. - PMC - PubMed
Adams 1997b {published data only}
    1. Adams WJ, Morris DL. Pilot study‐‐cimetidine enhances lymphocyte infiltration of human colorectal carcinoma: results of a small randomized control trial. Cancer 1997;80(1):15‐21. - PubMed
Kapoor 2005 {published data only}
    1. Kapoor S, Pal S, Sahni P, Dattagupta S, Kanti Chattopadhyay T. Effect of Pre‐Operative Short Course Famotidine on Tumor Infiltrating Lymphocytes in Colorectal Cancer: A Double Blind, Placebo Controlled, Prospective Randomized Study. Journal of Surgical Research 2005;129(2):172‐5. - PubMed
Kelly 1999 {published data only}
    1. Kelly MD, King J, Cherian M, Dwerryhouse SJ, Finlay IG, Adams WJ, et al. Randomized Trial of Preoperative Cimetidine in Patients with Colorectal Carcinoma with Quantitative Assessment of Tumor‐Associated Lymphocytes. Cancer 1999;85(8):1658‐63. - PubMed
Li 1999 {published data only}
    1. Li Y, Bai DJ, Wang K, Yang GL, Yuan HY, Shao H. Effects of perioperative cimetidine administration on natural killer cells in patients with gastrointestinal cancer. Chinese Journal of Cancer Research 1999;11(1):70‐3..
Lin 2004 {published data only}
    1. Lin CY, Bai DJ, Yuan HY, Wang K, Yang GL, Hu MB, et al. Perioperative cimetidine administration promotes peripheral blood lymphocytes and tumor infiltrating lymphocytes in patients with gastrointestinal cancer: Results of a randomized controlled clinical trial.. World Journal of Gastroenterology 2004;10(1):136‐42. - PMC - PubMed
Matsumoto 1995 {published data only}
    1. Matsumoto S. Cimetidine and survival with colorectal cancer. Lancet 1995;346(8967):115. - PubMed
Moesgaard 1998 {published data only}
    1. Moesgaard F, Jensen LS, Christiansen PM, Thorlacius‐Ussing O, Nielsen KT, Rasmussen NR, et al. The effect of ranitidine on postoperative infectious complications following emergency colorectal surgery: a randomized, placebo‐controlled, double‐blind trial. Inflammation research : Official journal of the European Histamine Research Society 1998;47(1):12‐7. - PubMed
Nielsen 1998 {published data only}
    1. Nielsen HJ, McArdle CS, Moesgaard F, Schulze S, et al. The effect of ranitidine on long‐term survival in primary colorectal cancer. A 40 months interim analysis. GI cancer 1998;2(3):227‐33.
Tavani 1998 {published data only}
    1. Tavani A, Fioretti F, Franceschi S, Vecchia C, Morris D.L, Adams W.J. Pilot study ‐ Cimetidine enhances lymphocyte infiltration of human colorectal carcinoma: Results of a small randomized control trial. Cancer 1998;82(11):2296‐7. - PubMed
Umemoto 1996 {published data only}
    1. Umemoto S. The effect of cimetidine as BRM ‐ Adjuvant immuno‐chemotherapy for colorectal carcinoma. Biotherapy 1996;10(3):511‐5.

Additional references

Abrams 2011
    1. Abrams TA, Brightly R, Mao J, Kirkner G, Meyerhardt JA, Schrag D, et al. Patterns of Adjuvant Chemotherapy Use in a Population‐Based Cohort of Patients With Resected Stage II or III Colon Cancer.. Journal of Clinical Oncology 2011;29(24):3255‐62. - PubMed
Adams 1997a
    1. Adams WJ, Morris DL. Pilot study‐‐cimetidine enhances lymphocyte infiltration of human colorectal carcinoma: results of a small randomized controlled trial. Cancer 1997;80(1):15‐21. - PubMed
Armitage 1979
    1. Armitage JO, Sidner RD. Antitumour effect of cimetidine. Lancet 1979;8121(1):882‐3. - PubMed
Eaton 2002
    1. Eaton D, Hawkins RE. Cimetidine in colorectal cancer ‐‐ are the effects immunological or adhesion‐mediated?. British Journal of Cancer 2002;86(2):159‐60. - PMC - PubMed
Flodgren 1985
    1. Flodgren P, Sjogren HO. Influence in vitro on NK and K cell activities by cimetidine and indomethacin with and without simultaneous exposure to interferon. Cancer Immunol Immunother 1985;19(1):28‐34. - PMC - PubMed
Gerard 2006
    1. Gerard JP, Conroy T, Bonnetain F, Bouche O, Chapet O, Closon‐Dejardin MT, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3‐4 rectal cancers: results of FFCD 9203.. Journal of Clinical Oncology 2006;24(28):4620‐5. - PubMed
Hansbrough 1986
    1. Hansbrough JF, Zapata‐Sirvent RL, Bender EM. Prevention of alterations in postoperative lymphocyte subpopulations by cimetidine and ibuprofen. Am J Surg 1986;151(2):249‐55. - PubMed
Harland 1989
    1. Harland CC, Saihan EM. Regression of cutaneous metastatic malignant melanoma with topical diphencyprone and oral cimetidine. Lancet 1989;8660(2):445. - PubMed
Harvey 1984
    1. Harvey VJ, Slevin ML, Dilloway MR, Clark PI, Johnston A, Lant AF. The influence of cimetidine on the pharmacokinetics of 5‐fluorouracil. British Journal of Clinical Pharmacology 1984;18(3):421‐30. - PMC - PubMed
Higgins 2002
    1. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine 2002;21:1539‐58. - PubMed
Hsiao 2011
    1. Hsiao FY, Mullins CD, Onukwugha E, Pandya N, Hanna N. Comparative Effectiveness of Different Chemotherapeutic Regimens on Survival of People Aged 66 and Older with Stage III Colon Cancer: A "Real World" Analysis Using Surveillance, Epidemiology, and End Results‐Medicare Data. Journal of the American Geriatrics Society 2011; (Electronic ahead of publication).;59(9):1717‐23. - PubMed
Imdahl 1995
    1. Imdahl A, Mantamadiotis T, Eggstein S, Farthmann EH, Baldwin GS. Expression of gastrin, gastrin/CCK‐B‐ and gastrin/CCK‐C receptors in human colorectal carcinomas.. Journal Cancer Res Clin Oncol 1995;121(11):661‐6. - PubMed
Jensen 1996
    1. Jensen LS, Kissmeyer‐Nielsen P, Wolff B, Qvist N. Randomised comparison of leucocyte‐depleted versus buffy‐coat‐poor blood transfusion and complications after colorectal surgery.. Lancet 1996;348(9031):841‐5. - PubMed
Kannagi 2004
    1. Kannagi R, Izawa M, Koike T, Miyazaki K, Kimura N. Carbohydrate‐mediated cell adhesion in cancer metastasis and angiogenesis. Cancer Sci 2004;95(5):377‐84. - PMC - PubMed
Katoh 1996
    1. Katoh J, Tsuchiya K, Sato W, Nakajima M, Iida Y. Cimetidine and immunoreactivity. Lancet 1996;9024(348):404‐5. - PubMed
Kobayashi 2000
    1. Kobayashi K, Matsumoto S, Morishima T, Kawabe T, Okamoto T. Cimetidine inhibits cancer cell adhesion to endothelial cells and prevents metastasis by blocking E‐selectin expression. Cancer Research 2000;60(14):3978‐84. - PubMed
Koh 1999
    1. Koh TJ, Dockray GJ, Varro A, Cahill RJ, Dangler CA, Fox JG, et al. Overexpression of glycine‐extended gastrin in transgenic mice results in increased colonic proliferation.. Jornal of Clinical Investigations 1999;103:1119‐26. - PMC - PubMed
Kojima 2002
    1. Kojima Y, Kondo T, Zhao QL, Shoji M, Futatsuya R. Protective effects of cimetidine on radiation‐induced micronuclei and apoptosis in human peripheral blood lymphocytes.. Free Radical Research 2002;36(3):255‐63. - PubMed
Kubota 2002
    1. Kubota T, Fujiwara H, Ueda Y, Itoh T, Yamashita T, Yoshimura T, et al. Cimetidine modulates the antigen presenting capacity of dendritic cells from colorectal cancer patients. British Journal of Cancer 2002;86(8):1257‐61. - PMC - PubMed
Kumar 1990
    1. Kumar A. Cimetidine: an immunomodulator. DICP; the annals of pharmacotherapy 1990;24(3):289‐295. - PubMed
Lefebvre 2008
    1. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies.. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration, 2008. Available from www.cochrane‐handbook.org.
Melmon 1972
    1. Melmon KL, Bourne HR, Weinstein J, Sela M. Receptors for histamine can be detected on the surface of selected leukocytes. Science 1972;177(50):707‐9. - PubMed
Mozdarani 2003
    1. Mozdarani H. Radioprotective properties of histamine H2 receptor antagonists: present and future prospects.. Journal of Radiation Research (Tokyo) 2003;44(2):145‐9. - PubMed
Nanda 1985
    1. Nanda NK, Nath I. Characteristics of histamine receptors present on suppressor T cells in "healthy individuals". International Journal of Immunopharmacology 1985;7(4):587‐95. - PubMed
Nielsen 1999
    1. Nielsen HJ, McArdle CS, Moesgaard F. The effect of ranitidine on postoperative infectious complications after elective colorectal surgery.. GI Cancer 1999;3(2):87‐95.
Ohsawa 2002
    1. Ohsawa T, Hirata W, Higichi S. Effects of three H2‐receptor antagonists (cimetidine, famotidine, ranitidine) on serum gastrin level. International Journal of Clinical Pharamacological Research 2002;22(2):29‐35. - PubMed
Orbuch 1996
    1. Orbuch M, Venzon DJ, Lubensky IA, Weber HC, Gibril F, Jensen RT. Prolonged hypergastrinemia does not increase the frequencyof colonic neoplasia in patients with Zollinger‐Ellison syndrome.. Digestive diseases and sciences. 1996;41:604‐13. - PubMed
Richter 1989
    1. Richter JM, Colditz GA, Huse DM, Delea TE, Oster G. Cimetidine and adverse reactions: a meta‐analysis of randomized clinical trials of short‐term therapy.. American Journal of Medicine 1989;87(3):278‐84. - PubMed
Robertson 2007
    1. Robertson DJ, Larsson H, Friis S, Pedersen L, Baron JA, Sorensen HT. Proton Pump Inhibitor Use and Risk of Colorectal Cancer: A Population‐Based, Case–Control Study.. Gastrenterology 2007;133:755‐60. - PubMed
Taylor 1988
    1. Taylor TV, Boom SJ, Blower AL, McMahon RF, Lawler W. Healing of a malignant gastric ulcer with cimetidine. J R Coll Surg Edinb 1988;33(6):339‐340. - PubMed
Tozeren 1995
    1. Tozeren A, Kleinman HK, Grant DS, Morales D, Mercurio AM, Byers SW. E‐selectin‐mediated dynamic interactions of breast‐ and colon‐cancer cells with endothelial‐cell monolayers. International Journal of Cancer 1995;60(3):426‐31. - PubMed
Trudeau 1970
    1. Trudeau WL, McGuigan JE. Serum gastrin levels in patientswith peptic ulcer disease. Gastroenterology 1970;59:6‐12. - PubMed
Zhang 2006
    1. Zhang S, Lovejoy KS, Shima JE, Lagpacan LL, Shu Y, Lapuk A, et al. Organic cation transporters are determinants of oxaliplatin cytotoxicity.. Cancer Research 2006;66(17):8847‐57. - PMC - PubMed

MeSH terms

LinkOut - more resources